Document is current
Any future updates will be listed below
-
Authors
Van Lent, Jonas
Prior, Robert
Pérez Siles, Gonzalo
Cutrupi, Anthony N.
Kennerson, Marina L.
Vangansewinkel, Tim
Wolfs, Esther
Mukherjee-Clavin, Bipasha
Nevin, Zachary https://orcid.org/0000-0003-4987-924X
Judge, Luke
Conklin, Bruce https://orcid.org/0000-0003-1463-6061
Tyynismaa, Henna
Clark, Alex J.
Bennett, David L. https://orcid.org/0000-0002-7996-2696
Van Den Bosch, Ludo https://orcid.org/0000-0003-0104-4067
Saporta, Mario
Timmerman, Vincent https://orcid.org/0000-0002-2162-0933
- License Information
-
More Information
Article History
Received: 10 November 2023
Revised: 21 February 2024
Accepted: 18 March 2024
First Online: 3 June 2024
Competing interests
: D.L.B. has acted as a consultant in the last 2 years for AditumBio, Biointervene, Combigene, LatigoBio, GSK, Ionis, Lexicon Therapeutics, Neuvati, Olipass, Orion, Replay, SC Health Managers, Third Rock Ventures and Vida Ventures on behalf of Oxford University Innovation. L.V.D.B. is head of the Scientific Advisory Board of Augustine Therapeutics (Leuven, Belgium) and is part of the Investment Advisory Board of Droia Ventures (Meise, Belgium).
